Study study type PathologyT1T0Patientssample sizesROB Results

Extensive stage SCLC (Es-SCLC) - 1st Line (L1) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - 1st Line (L1)

versus etoposide plus platin
durvalumab plus tremelimumab plus SoC
CASPIAN (DT ; all population), 2019
  NCT03043872
RCTExtensive stage SCLC (Es-SCLC) - 1st Line (L1)durvalumab plus tremelimumab and etoposide plus either cisplatin or carboplatinetoposide plus either cisplatin or carboplatinadults with untreated extensive-stage small-cell lung cancer (SCLC)268 / 269some concern
inconclusive
  • inconclusive 18 % decrease in deaths (OS) (PE)